Price
$237.47+10.76%Social Signal Score
Analyst Ratings
14 analystsRevenue
$1.59B+145.62%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel A. Carestio
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Employees
- 17,937
- Beta
- 0.86
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 5.84
Financials
Revenue
$1.59B+145.6%Net Income
$213.70MEBITDA
$299.20M+417.6%Free Cash Flow
$212.70M+240.1%EPS (diluted)
$2.19Shares Outstanding (diluted)
97.60M+14.7%Operating Expenses
$397.50MCash & Debt
$531.10MReturn of Capital
$167.40MRevenue by Segment (annual)
$5.94BDividend per Share
$0.69Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $5.94B | $785.10M | $7.93 |
| 2025 | $5.46B | $614.64M | $6.24 |
| 2024 | $5.14B | $378.24M | $3.83 |
| 2023 | $4.54B | $107.03M | $1.07 |
| 2022 | $4.22B | $243.89M | $2.50 |
| 2021 | $3.11B | $397.40M | $4.66 |
| 2020 | $3.03B | $407.66M | $4.81 |
| 2019 | $2.78B | $304.05M | $3.59 |
| 2018 | $2.62B | $290.92M | $3.42 |
| 2017 | $2.61B | $109.97M | $1.29 |
| 2016 | $2.24B | $110.76M | $1.57 |
| 2015 | $1.85B | $135.06M | $2.27 |
| 2014 | $1.62B | $129.44M | $2.20 |
| 2013 | $1.50B | $159.98M | $2.74 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from STE's reported EPS growth of 8.5% a year over 13 years.
- EPS in 5 years
- $12.02
- Implied price
- $336.60
- Return from $255.76
- 5.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $167.35 — -34.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 20 | 24 | 28 | 32 | 36 |
|---|---|---|---|---|---|
| -1.5% | -10.3% | -7.0% | -4.1% | -1.5% | 0.9% |
| 3.5% | -5.8% | -2.3% | 0.8% | 3.5% | 6.0% |
| 8.5% | -1.2% | 2.4% | 5.6% | 8.5% | 11.1% |
| 13.5% | 3.3% | 7.2% | 10.5% | 13.5% | 16.2% |
| 18.5% | 7.9% | 11.9% | 15.4% | 18.5% | 21.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (17)
- Newsmarketbeat.com·15d ago·Positive
What STERIS (STE) Said on Its Q2 Earnings Call STERIS NYSE: STE raised its fiscal 2027 earnings outlook after reporting higher second-quarter revenue and profit, as tariff refunds helped expand margins and strong Life Sciences equipment shipments offset a slower start to the year in its sterilization business.
View source ↗ - Newszacks.com·18d ago·Negative
Compared to Estimates, Steris (STE) Q2 Earnings: A Look at Key Metrics Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newsglobenewswire.com·18d ago·Negative
STERIS Announces Financial Results for Fiscal 2027 Second Quarter DUBLIN, IRELAND, Nov. 04, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2027 second quarter ended September 30, 2026. Total revenue for the second quarter of fiscal 2027 increased 9% to $1.6 billion compared with $1.5 billion in the second quarter of fiscal 2026. Constant currency organic revenue growth was 8% in the second quarter.
View source ↗ - Newszacks.com·23d ago·Neutral
STERIS Set to Report Q2 Earnings: What's in the Cards for the Stock? STE's second-quarter fiscal 2027 earnings may benefit from Healthcare growth, recent acquisitions, easing AST comparisons and continued margin expansion.
View source ↗ - News (Marketaux)manilatimes.net·25d ago·Positive
STERIS Announces Dividend of $0.69 per share DUBLIN, IRELAND, Oct. 28, 2026 (GLOBE NE[+319 characters]
View source ↗ - News (RSS)investing·25d ago·Neutral
STERIS declares $0.69 quarterly dividend payable in December
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
STERIS Announces Dividend of $0.69 per share DUBLIN, IRELAND, Oct. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.69 per share. The dividend is payable on December 17, 2026, to shareholders of record at the close of business on November 17, 2026.
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
STERIS to Host a Conference Call for Fiscal 2027 Second Quarter on November 5, 2026 DUBLIN, IRELAND, Oct. 20, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2027 second quarter results at 9:00 a.m. ET on November 5, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join t…
View source ↗ - Newszacks.com·37d ago·Positive
Reasons to Add STE Stock to Your Portfolio Right Now STERIS' strong Healthcare growth, improving AST prospects and rising Life Sciences demand bolster its outlook, despite tariff and inflationary pressures.
View source ↗ - Newsprnewswire.com·41d ago·Negative
Xodus Medical Announces Agreement to Be Acquired by STERIS (NYSE: STE) PITTSBURGH, Oct. 12, 2026 /PRNewswire/ -- Xodus Medical, a leading developer and manufacturer of innovative surgical safety solutions, today announced that it has entered into an agreement to be acquired by STERIS, a global provider of products and services that support patient care with an emphasis on infection prevention. The acquisition represents a significant milestone in Xodus Medical's more than 30-year history, bringi…
View source ↗ - News (RSS)barrons·41d ago·Neutral
Steris to Acquire Xodus Medical for $2.1 Billion The Dublin, Ireland provider of products and services to hospitals and pharmaceutical manufacturers said it expects the deal to expand its portfolio.
View source ↗ - Newswsj.com·41d ago·Neutral
Steris to Acquire Xodus Medical for $2.1 Billion The Dublin, Ireland provider of products and services to hospitals and pharmaceutical manufacturers said it expects the deal to expand its portfolio.
View source ↗ - Newsseekingalpha.com·68d ago·Positive
STERIS plc (STE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript STERIS plc (STE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·82d ago·Neutral
STERIS to Present at the Morgan Stanley Healthcare Conference Dublin, Ireland, Sept. 01, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will participate in the Morgan Stanley Healthcare Conference in New York City on Tuesday, September 15, 2026.
View source ↗ - Newszacks.com·93d ago·Neutral
Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales? STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.
View source ↗ - Newszacks.com·94d ago·Positive
Should Investors Buy STERIS as Growth Meets Reasonable Valuation? STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.
View source ↗ - Newsmarketbeat.com·105d ago·Neutral
STERIS Q1 Earnings Call Highlights STERIS NYSE: STE reported first-quarter fiscal 2027 revenue growth and higher earnings, while maintaining its full-year outlook and outlining a $600 million investment in a new chemistry manufacturing, research and distribution complex in North Carolina.
View source ↗
Earnings
Wed, Feb 3(in 2 months)
Consensus estimate $2.80 per share
Typical surprise +4.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$2.94 vs $2.68beat
- Wed, Aug 5$2.59 vs $2.49beat
- Mon, May 11$2.83 vs $2.85miss
- Wed, Feb 4$2.53 vs $2.53beat
- Wed, Nov 5$2.47 vs $2.35beat
- Wed, Aug 6$2.34 vs $2.26beat
Estimates and results for STE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by STE officers and directors.
- Bought
- —
- Sold
- $12.4m
0 trades
16 trades
- Madsen Juliasold
- Burton Karen Lsold
- Sohi Mohsensold
- Sohi Mohsensold
- Sohi Mohsensold
- Zangerle John Adamsold
- Carestio Daniel Asold
- Carestio Daniel Asold
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (33d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (14d later)Sell$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (13d later)Sell$15,001 - $50,000
- April McClain Delaneyhouse · MD06 · disclosed Sep 10, 2026 (16d later)Sell$100,001 - $250,000
- Jared Moskowitzhouse · FL23 · disclosed Aug 28, 2026 (46d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Aug 4, 2026 (11d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Aug 4, 2026 (6d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Aug 4, 2026 (4d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Aug 4, 2026 (8d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jun 9, 2026 (29d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jun 9, 2026 (27d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed May 11, 2026 (10d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed May 11, 2026 (12d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed May 7, 2026 (7d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Apr 8, 2026 (23d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Mar 11, 2026 (33d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Mar 10, 2026 (28d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Oct 7, 2025 (26d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Oct 7, 2025 (19d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
